| human | Q5 |
| P10762 | IRIS UNIMORE author ID | 07667 |
| P10055 | IRIS Verona author ID | 57998 |
| P496 | ORCID iD | 0000-0002-5210-5344 |
| P11597 | Padua Research Archive author ID | 04392 |
| P1053 | ResearcherID | F-7418-2014 |
| P1153 | Scopus author ID | 35926767000 |
| P108 | employer | University of Padua | Q193510 |
| P734 | family name | Conte | Q16865732 |
| Conte | Q16865732 | ||
| Conte | Q16865732 | ||
| P735 | given name | Pierfranco | Q43382027 |
| Pierfranco | Q43382027 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q38989266 | 18F-Fluoroestradiol Positron Emission Tomography in Breast Cancer Patients: Systematic Review of the Literature & Meta-Analysis. |
| Q40127291 | 5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial |
| Q43688729 | 5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer. |
| Q44752777 | 5-fluorouracil administered as a 48-hour semiintermittent infusion in combination with leucovorin, cisplatin and epirubicin: phase II study in advanced gastric cancer patients. |
| Q50726988 | A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study). |
| Q64061324 | A Novel 3D In Vitro Platform for Pre-Clinical Investigations in Drug Testing, Gene Therapy, and Immuno-oncology |
| Q54197425 | A Triple Rare E709K and L833V/H835L EGFR Mutation Responsive to an Irreversible Pan-HER Inhibitor: A Case Report of Lung Adenocarcinoma Treated with Afatinib. |
| Q37644553 | A catalyst for change: the European cancer Patient's Bill of Rights |
| Q43122434 | A computational workflow for the design of irreversible inhibitors of protein kinases. |
| Q36413053 | A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing. |
| Q87438374 | A phase I clinical and pharmacokinetic study evaluating vinflunine in combination with epirubicin as first-line treatment in metastatic breast cancer |
| Q45024922 | A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancer |
| Q68878800 | A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer |
| Q36892821 | A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer. |
| Q43512086 | Abdominopelvic radiotherapy following surgery and chemotherapy in advanced ovarian cancer |
| Q70880430 | Accelerated epirubicin-ifosfamide-dacarbazine regimen in patients with adult soft tissue sarcomas |
| Q44299813 | Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer. |
| Q36696923 | Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy. |
| Q37177107 | Adipose stromal/stem cells assist fat transplantation reducing necrosis and increasing graft performance. |
| Q43100976 | Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy |
| Q38673148 | Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel |
| Q44572704 | Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC). |
| Q34729388 | Alpha-2B-interferon plus floxuridine in metastatic renal cell carcinoma. A phase I-II study. |
| Q43264871 | An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. |
| Q72587392 | Analysis of time to response to chemotherapy in 316 metastatic breast cancer patients |
| Q51116689 | Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM. |
| Q41663662 | Anthracyclines-paclitaxel combinations in the treatment of breast cancer. |
| Q36703918 | Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective. |
| Q36610680 | Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. |
| Q64288089 | Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer |
| Q92255228 | BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysis |
| Q43111250 | Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer |
| Q31020945 | Bevacizumab in ovarian cancer: Focus on clinical data and future perspectives. |
| Q48220922 | Beyond breast specific-Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome |
| Q82286610 | Biomarkers predicting clinical benefit: fact or fiction? |
| Q59300354 | Body Mass Index and Prognosis of Metastatic Breast Cancer Patients Receiving First-Line Chemotherapy |
| Q64072441 | Bone metastases from head and neck malignancies: Prognostic factors and skeletal-related events |
| Q30966783 | Braf mutation in interdigitating dendritic cell sarcoma: a case report and review of the literature |
| Q94407728 | CMET-29. HORMONE RECEPTORS STATUS: A STRONG DETERMINANT OF THE KINETICS OF BRAIN METASTASES OCCURRENCE COMPARED WITH HER2 STATUS IN BREAST CANCER |
| Q37334564 | Cancer Control in Central and Eastern Europe |
| Q70222895 | Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma |
| Q36613992 | Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study |
| Q69694424 | Cell kinetics in ovarian cancer. Relationship to clinicopathologic features, responsiveness to chemotherapy, and survival |
| Q47676268 | Chemotherapy for advanced HER2-negative breast cancer: Can one algorithm fit all? |
| Q31962966 | Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group |
| Q68583219 | Chemotherapy versus radiotherapy in the management of ovarian cancer patients with pathological complete response or minimal residual disease at second look |
| Q71611894 | Chemotherapy with or without estrogenic recruitment in metastatic breast cancer. A randomized trial of the Gruppo Oncologico Nord Ovest (GONO) |
| Q67926547 | Cisplatin and 5-fluorouracil in refractory breast cancer patients: a phase II study |
| Q70079139 | Cisplatin, methotrexate, and 5-fluorouracil combination chemotherapy for advanced ovarian cancer |
| Q90637002 | Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy |
| Q96585639 | Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World Experience |
| Q33779181 | Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations |
| Q47727133 | Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs? |
| Q46466675 | Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management |
| Q37316281 | Complete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab: a case report. |
| Q38355618 | Complete response to weekly carboplatin-docetaxel chemotherapy in a 91-year-old woman with anaplastic thyroid cancer |
| Q45014464 | Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial. |
| Q36125244 | Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature. |
| Q58465920 | Corrigendum to “Gene expression profiling in breast cancer: A clinical perspective” [The Breast 22 (2013) 109–120] |
| Q40888969 | Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment? |
| Q38584437 | Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment |
| Q84332729 | Cytogenetic abnormalities and clinical features in a patient cohort affected by three or more synchronous or metachronous primitive malignancies |
| Q91693727 | De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study |
| Q39462829 | Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. |
| Q57758305 | Diagnosis, Management and Clinical Outcome of Bone Metastases in Breast Cancer Patients: Results from a Prospective, Multicenter Study |
| Q52945391 | Diagnostic and prognostic impact of fluorine-18-fluorodeoxyglucose PET/CT in preoperative and postoperative setting of breast cancer patients. |
| Q67233558 | Diethylstilbestrol (DES) and recombinant human growth hormone (rhGH) as modulators of breast cancer proliferative activity |
| Q73494763 | Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer |
| Q97566404 | ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer |
| Q72079985 | Early B lymphocytes in man |
| Q71126580 | Effects of primary chemotherapy on biological parameters of locally advanced breast cancer |
| Q37247194 | Effects of sulfonylureas on tumor growth: a review of the literature |
| Q92066447 | Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity |
| Q38761445 | Endocrine therapy in post-menopausal women with metastatic breast cancer: From literature and guidelines to clinical practice. |
| Q37977498 | Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer |
| Q36485352 | Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry. |
| Q46190706 | Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer. |
| Q72443848 | Epidoxorubicin and lonidamine in refractory or recurrent epithelial ovarian cancer |
| Q77059564 | Epirubicin/vinorelbine as first line therapy in metastatic breast cancer |
| Q42548566 | Erratum to: 'Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized con |
| Q50862894 | Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials. |
| Q45761502 | European Perspectives: A Dialogue with the European Oncology Community |
| Q72663417 | Evaluation of taxol cardiotoxicity in metastatic breast cancer |
| Q69592203 | Evaluation of the ovarian cancer antigen, Ca-125, as a tumor marker |
| Q47712466 | External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience |
| Q34745831 | FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer. |
| Q30249805 | Fat grafting for breast cancer patients: From basic science to clinical studies |
| Q33411292 | Fatal oxaliplatin-induced thrombotic thrombocytopenic purpura: a case report |
| Q73280958 | Filgrastim and lack of support of intensive adjuvant chemotherapy for high-risk breast cancer patients |
| Q47604446 | First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer |
| Q92205795 | From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study) |
| Q94362018 | Future role of bevacizumab in breast cancer |
| Q33761830 | GD2 expression in breast cancer. |
| Q73478594 | Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study |
| Q33344322 | Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens |
| Q38086710 | Gene expression profiling in breast cancer: a clinical perspective. |
| Q77538098 | Germline mutations of the BRCA1-associated ring domain (BARD1) gene in breast and breast/ovarian families negative for BRCA1 and BRCA2 alterations |
| Q91626887 | HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade |
| Q92048299 | Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): Do gender and sex matter? |
| Q43542641 | High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC). |
| Q51835410 | Histology-based Combination Induction Chemotherapy for Elderly Patients with Clinical Stage III Non-small Cell Lung Cancer. |
| Q53445409 | Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer. |
| Q51663342 | Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer. |
| Q92425244 | Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges |
| Q92451331 | Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study |
| Q54348933 | Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials. |
| Q43871123 | Impact of two different dose-intensity chemotherapy regimens on psychological distress in early breast cancer patients. |
| Q35821531 | Impressive Response to Dose-Dense Chemotherapy in a Patient with NUT Midline Carcinoma. |
| Q44874118 | In vivo manipulation of human breast cancer growth by estrogens and growth hormone: kinetic and clinical results. |
| Q59729563 | Incidence and Clinical Impact of Sterilized Disease and Minimal Residual Disease After Preoperative Radiochemotherapy for Rectal Cancer |
| Q74023986 | Increased prevalence of primary hyperparathyroidism in treated breast cancer |
| Q112721473 | Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy |
| Q73143097 | Infusions of fluorouracil and leucovorin: effects of the timing and semi-intermittency of drug delivery |
| Q42497114 | Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial |
| Q53460208 | Interferon-alpha or beta potentiate platinum analogous in human glioblastoma cell lines. |
| Q37951426 | International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). |
| Q39128685 | Intraperitoneal Chemotherapy in Patients Pretreated for Ovarian Cancer Matched with Patients Treated with Parenteral Chemotherapy |
| Q37076400 | Intraperitoneal chemotherapy in the management of patients with advanced epithelial ovarian cancer: a critical review of the literature. |
| Q73358276 | Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest |
| Q33762423 | Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies |
| Q39001187 | LKB1 Expression Correlates with Increased Survival in Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab |
| Q64251353 | LKB1 and Tumor Metabolism: The Interplay of Immune and Angiogenic Microenvironment in Lung Cancer |
| Q51934866 | Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. |
| Q53486230 | Laparoscopic approach of gastric gastrointestinal stromal tumors (GISTs): is it still a courageous choice? Report of two cases. |
| Q46577618 | Letrozole versus letrozole plus Lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: a double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB). |
| Q74216422 | Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors |
| Q60691417 | Long-term prognosis following macroscopic complete response at second-look laparotomy in advanced ovarian cancer patients treated with platinum-based chemotherapy |
| Q56749926 | Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer |
| Q44723581 | Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients. |
| Q31019143 | MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data |
| Q84992912 | MSC and Tumors: Homing, Differentiation, and Secretion Influence Therapeutic Potential |
| Q64244641 | MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic Adenocarcinoma |
| Q53080309 | Magnetic resonance imaging and ultrasonography in predicting infiltrating residual disease after preoperative chemotherapy in stage II-III breast cancer. |
| Q38222277 | Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents |
| Q52728166 | Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intra-tumor heterogeneity over time. |
| Q44146396 | Management and treatment of triple-negative breast cancer patients from the NEMESI study: an Italian experience. |
| Q73597514 | Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Clinical evidence of significant antitumor activity and enhancement of zidovudine-induced DNA single strand |
| Q70292826 | Megestrol acetate: phase II study of a single daily administration in advanced breast cancer |
| Q56097549 | Mesenchymal Progenitors Aging Highlights a miR-196 Switch Targeting HOXB7 as Master Regulator of Proliferation and Osteogenesis |
| Q38938230 | Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas |
| Q37553634 | Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy |
| Q33488092 | Mitomycin-ifosfamide-cisplatinum (MIP) vs MIP-interferon vs cisplatinum-carboplatin in metastatic non-small-cell lung cancer: a FONICAP randomised phase II study. Italian Lung Cancer Task Force. |
| Q52983259 | Morphological and genetic heterogeneity in multifocal lung adenocarcinoma: The case of a never-smoker woman. |
| Q36625974 | Multicenter randomized phase III trial of epirubicin plus paclitaxel vs epirubicin followed by paclitaxel in metastatic breast cancer patients: focus on cardiac safety |
| Q71132148 | Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer |
| Q46295115 | Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278). |
| Q46250628 | Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer. |
| Q92477604 | Neoplastic Pericardial Effusion: A Monocentric Retrospective Study |
| Q92487063 | Neutrophil-lymphocyte ratio is prognostic in early stage resected small-cell lung cancer |
| Q91468046 | Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡ |
| Q26777427 | Non-Small Cell Lung Cancer in a Very Young Woman: A Case Report and Critical Review of the Literature |
| Q95827184 | Novel Nuclear Medicine Imaging Applications in Immuno-Oncology |
| Q91582070 | Olaparib for advanced breast cancer |
| Q57112150 | Olaparib for the treatment of breast cancer |
| Q64242044 | OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer |
| Q98732997 | Oncological care organisation during COVID-19 outbreak |
| Q73129575 | Oral doxifluridine in advanced hepatocellular carcinoma: A phase II study |
| Q34082928 | Ovarian cancer: optimal chemotherapy in relapsed disease. |
| Q98725688 | PIK3CA mutation in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer: association with prognosis and integration with PAM50 subtype |
| Q88492542 | PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab |
| Q39767744 | PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. |
| Q71785902 | Paclitaxel and vinorelbine in anthracycline-pretreated breast cancer: a phase II study |
| Q91894734 | Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer |
| Q92846910 | Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial |
| Q64099217 | Patterns of Fertility Preservation and Pregnancy Outcome After Breast Cancer at a Large Comprehensive Cancer Center |
| Q34649644 | Pemetrexed: a promising new treatment for breast cancer. |
| Q90250960 | Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors |
| Q54525297 | Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. |
| Q41726699 | Pharmacokinetic optimisation of the treatment of cancer with high dose zidovudine. |
| Q33747098 | Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer. |
| Q34696189 | Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs. |
| Q35803848 | Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients |
| Q58614874 | Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer |
| Q71808061 | Phase II study of oral doxifluridine in elderly patients with advanced non-small-cell lung cancer |
| Q71751992 | Phase II study of vinorelbine/ifosfamide/cisplatin for the treatment of advanced non-small-cell lung cancer |
| Q72520138 | Phase II trial of 5-fluorouracil and the natural l isomer of folinic acid in the treatment of advanced colorectal carcinoma |
| Q62392233 | Phase II, randomized trial of preoperative epirubicin-paclitaxel +/− gefitinib with biomarker evaluation in operable breast cancer |
| Q36379813 | Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial |
| Q43286766 | Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1. |
| Q33954595 | Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates. |
| Q60682608 | Posterior Reversible Encephalopathy Syndrome During Ipilimumab Therapy for Malignant Melanoma |
| Q41521402 | Potentiation of TNF-mediated cell killing by mitoxantrone. Relationship to DNA single-strand break formation. |
| Q41596840 | Potentiation of topoisomerase I and II inhibitors cell killing by tumor necrosis factor: relationship to DNA strand breakage formation |
| Q68200996 | Prediction of survival by thymidine labelling index in patients with resistant ovarian carcinoma |
| Q36309380 | Predictive value of biologic parameters for primary chemotherapy in operable breast cancer. |
| Q60682610 | Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis |
| Q60682604 | Preoperative Carboplatin–Paclitaxel–Bevacizumab in Triple-Negative Breast Cancer: Final Results of the Phase II Ca.Pa.Be Study |
| Q46487408 | Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB Trial). |
| Q51327778 | Present and future breast cancer management--bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry. |
| Q77809268 | Primary chemotherapy in locally advanced breast cancer (LABC): effects on tumour proliferative activity, bcl-2 expression and the relationship between tumour regression and biological markers |
| Q36571356 | Primary systemic therapy for operable breast cancer: a review of clinical trials and perspectives |
| Q80185978 | Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy |
| Q35879081 | Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials |
| Q38719132 | Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation |
| Q34250130 | Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy. |
| Q59729497 | Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapy |
| Q37600494 | Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study |
| Q42328025 | Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study |
| Q69733942 | Proliferative activity of human solid tumors evaluated by thymidine labeling index and primer-dependent alpha-DNA polymerase |
| Q36614865 | Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma. |
| Q36064908 | Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer |
| Q80337028 | Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria |
| Q78020065 | Protracted continuous infusion of 5-fluorouracil and low-dose leucovorin in patients with metastatic colorectal cancer resistant to 5-fluorouracil bolus-based chemotherapy: a phase II study |
| Q44891038 | Pulmonary strongyloidiasis mimicking cancer symptoms: a case of hyperinfection in a patient with metastatic lung cancer. |
| Q48666084 | Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer |
| Q77182264 | Radio-frequency thermal ablation of liver metastases with a cooled-tip electrode needle: results of a pilot clinical trial |
| Q37042501 | Radiological response and survival in locally advanced non-small-cell lung cancer patients treated with three-drug induction chemotherapy followed by radical local treatment |
| Q36694220 | Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the Mario Negri Inst |
| Q27824835 | Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group |
| Q73008980 | Rapid intravenous premedication with dexamethasone prevents hypersensitivity reactions to paclitaxel |
| Q34005143 | Rare breast cancer subtypes: histological, molecular, and clinical peculiarities |
| Q60691431 | Recurrent ovarian carcinoma: Salvage treatment with platinum in patients responding to first-line platinum-based regimens |
| Q38120666 | Relapsed triple-negative breast cancer: challenges and treatment strategies |
| Q92413714 | Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer |
| Q46825019 | Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 Years. |
| Q37351061 | Restoration and reversible expansion of the osteoblastic hematopoietic stem cell niche after marrow radioablation. |
| Q45044547 | Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. |
| Q39660526 | Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study |
| Q48257534 | Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial. |
| Q33433527 | Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, [...] |
| Q35905967 | Safety of intravenous and oral bisphosphonates and compliance with dosing regimens |
| Q40564796 | Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report. |
| Q41505046 | Significance of lymph node sampling in epithelial carcinoma of the ovary. |
| Q43503224 | Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients. |
| Q61797115 | Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer |
| Q57757985 | Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study |
| Q26765060 | Squamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterization |
| Q72388247 | Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II study |
| Q31003726 | Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies |
| Q69626573 | Survival of patients with relapsing breast cancer: analysis of 302 patients |
| Q41501161 | Synergistic antiproliferative activity of suramin and alpha 2A-interferon against human colorectal adenocarcinoma cell lines: in vitro studies. |
| Q41624971 | Synergistic cytotoxic effects of recombinant human tumor necrosis factor and Etoposide (VP16) or Doxorubicin on A2774 human epithelial ovarian cancer cell line. |
| Q41279899 | Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists |
| Q40674553 | Tamoxifen and interferon-beta for the treatment of metastatic breast cancer. |
| Q68312981 | Tamoxifen rechallenge |
| Q38186452 | Targeting bone metastatic cancer: Role of the mTOR pathway |
| Q90348397 | The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial |
| Q55412581 | The European Cancer Patient's Bill of Rights, update and implementation 2016. |
| Q60682607 | The Future of Chemotherapy in the Era of Personalized Medicine |
| Q45925449 | The clinical relevance of endocrine-therapy-induced changes in lipid metabolism in breast cancer patients. |
| Q35755601 | The curability of breast cancer and the treatment of advanced disease. |
| Q70534404 | The impact of received dose intensity on the outcome of advanced ovarian cancer |
| Q38011294 | The next generation of biologic agents: therapeutic role in relation to existing therapies in metastatic breast cancer |
| Q69388718 | The role of surgery in the combined treatment of locally advanced breast cancer |
| Q26997396 | The sequential use of endocrine treatment for advanced breast cancer: where are we? |
| Q35577964 | The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer. |
| Q90768447 | Therapeutic approaches for T790M mutation positive non-small-cell lung cancer |
| Q61917301 | Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy |
| Q57171850 | Therapeutic perspectives for brain metastases in non-oncogene addicted non-small cell lung cancer (NSCLC): Towards a less dismal future? |
| Q61952845 | Thymidine labelling index as prognostic factor in resected non-small cell lung cancer |
| Q70795750 | Timed sequential chemotherapy following drug-induced kinetic recruitment in refractory ovarian cancer |
| Q68801478 | Timed sequential chemotherapy following ifosfamide-induced kinetic recruitment in refractory ovarian cancer |
| Q37821896 | Timing for starting second-line therapy in recurrent ovarian cancer |
| Q85458749 | Trabectedin plus pegylated liposomal doxorubicin: retrospective analysis in heavily pretreated platinum-sensitive ovarian cancer |
| Q39068453 | Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. |
| Q91986598 | Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE |
| Q71539558 | Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization |
| Q71702250 | Treatment of metastatic renal cell carcinoma with constant-rate floxuridine infusion plus recombinant alpha 2b-interferon |
| Q50862543 | Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials. |
| Q72031166 | Tumour kinetics, response to chemotherapy and survival in primary ovarian cancer |
| Q92119715 | Use of Electronic Administrative Databases to Measure Quality Indicators of Breast Cancer Care: Experience of Five Regional Oncology Networks in Italy |
| Q83510000 | Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey |
| Q47944718 | Using the expected survival to explain differences between the results of randomized trials: a case in advanced ovarian cancer |
| Q39616417 | Uterine sarcomas: a clinicopathologic study. |
| Q91359171 | Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial |
| Q61898836 | Weekly Low-Dose Paclitaxel as Maintenance Treatment in Patients With Advanced Ovarian Cancer Who Had Microscopic Residual Disease at Second-Look Surgery After 6 Cycles of Paclitaxel/Platinum-Based Chemotherapy |
| Q44281706 | Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer. |
| Q53166630 | Whole exome sequencing of rare aggressive breast cancer histologies. |
Search more.